269 related articles for article (PubMed ID: 25724305)
1. Splicing analysis of 14 BRCA1 missense variants classifies nine variants as pathogenic.
Ahlborn LB; Dandanell M; Steffensen AY; Jønson L; Nielsen FC; Hansen TV
Breast Cancer Res Treat; 2015 Apr; 150(2):289-98. PubMed ID: 25724305
[TBL] [Abstract][Full Text] [Related]
2. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members.
Thomassen M; Blanco A; Montagna M; Hansen TV; Pedersen IS; Gutiérrez-Enríquez S; Menéndez M; Fachal L; Santamariña M; Steffensen AY; Jønson L; Agata S; Whiley P; Tognazzo S; Tornero E; Jensen UB; Balmaña J; Kruse TA; Goldgar DE; Lázaro C; Diez O; Spurdle AB; Vega A
Breast Cancer Res Treat; 2012 Apr; 132(3):1009-23. PubMed ID: 21769658
[TBL] [Abstract][Full Text] [Related]
3. Additional molecular and clinical evidence open the way to definitive IARC classification of the BRCA1 c.5332G > A (p.Asp1778Asn) variant.
Minucci A; Lalle M; De Leo R; Mazzuccato G; Scambia G; Urbani A; Fagotti A; Concolino P; Capoluongo E
Clin Biochem; 2019 Jan; 63():54-58. PubMed ID: 30315757
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of BRCA1 gene variants by mini-gene splicing assay.
Steffensen AY; Dandanell M; Jønson L; Ejlertsen B; Gerdes AM; Nielsen FC; Hansen Tv
Eur J Hum Genet; 2014 Dec; 22(12):1362-8. PubMed ID: 24667779
[TBL] [Abstract][Full Text] [Related]
5. Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
Chen X; Truong TT; Weaver J; Bove BA; Cattie K; Armstrong BA; Daly MB; Godwin AK
Hum Mutat; 2006 May; 27(5):427-35. PubMed ID: 16619214
[TBL] [Abstract][Full Text] [Related]
6. The BRCA1 c.5434C->G (p.Pro1812Ala) variant induces a deleterious exon 23 skipping by affecting exonic splicing regulatory elements.
Gaildrat P; Krieger S; Théry JC; Killian A; Rousselin A; Berthet P; Frébourg T; Hardouin A; Martins A; Tosi M
J Med Genet; 2010 Jun; 47(6):398-403. PubMed ID: 20522429
[TBL] [Abstract][Full Text] [Related]
7. Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance.
Langerud J; Jarhelle E; Van Ghelue M; Ariansen SL; Iversen N
Hum Genomics; 2018 Nov; 12(1):51. PubMed ID: 30458859
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing.
Brandão RD; van Roozendaal K; Tserpelis D; Gómez García E; Blok MJ
Breast Cancer Res Treat; 2011 Oct; 129(3):971-82. PubMed ID: 21638052
[TBL] [Abstract][Full Text] [Related]
9. The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding.
Millevoi S; Bernat S; Telly D; Fouque F; Gladieff L; Favre G; Vagner S; Toulas C
Breast Cancer Res Treat; 2010 Apr; 120(2):391-9. PubMed ID: 19404736
[TBL] [Abstract][Full Text] [Related]
10. Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.
Jarhelle E; Riise Stensland HM; Mæhle L; Van Ghelue M
Fam Cancer; 2017 Jan; 16(1):1-16. PubMed ID: 27495310
[TBL] [Abstract][Full Text] [Related]
11. Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site.
Brewster BL; Rossiello F; French JD; Edwards SL; Wong M; Wronski A; Whiley P; Waddell N; Chen X; Bove B; ; Hopper JL; John EM; Andrulis I; Daly M; Volorio S; Bernard L; Peissel B; Manoukian S; Barile M; Pizzamiglio S; Verderio P; Spurdle AB; Radice P; Godwin AK; Southey MC; Brown MA; Peterlongo P
Hum Mutat; 2012 Dec; 33(12):1665-75. PubMed ID: 22753153
[TBL] [Abstract][Full Text] [Related]
12. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
[TBL] [Abstract][Full Text] [Related]
13. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
[TBL] [Abstract][Full Text] [Related]
14. Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.
Lovelock PK; Healey S; Au W; Sum EY; Tesoriero A; Wong EM; Hinson S; Brinkworth R; Bekessy A; Diez O; Izatt L; Solomon E; Jenkins M; Renard H; Hopper J; Waring P; Tavtigian SV; Goldgar D; Lindeman GJ; Visvader JE; Couch FJ; Henderson BR; Southey M; Chenevix-Trench G; Spurdle AB; Brown MA;
J Med Genet; 2006 Jan; 43(1):74-83. PubMed ID: 15923272
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of semi-quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes.
Montalban G; Bonache S; Moles-Fernández A; Gadea N; Tenés A; Torres-Esquius S; Carrasco E; Balmaña J; Diez O; Gutiérrez-Enríquez S
Hum Mutat; 2019 Dec; 40(12):2296-2317. PubMed ID: 31343793
[TBL] [Abstract][Full Text] [Related]
16. A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance.
Caligo MA; Bonatti F; Guidugli L; Aretini P; Galli A
Hum Mutat; 2009 Jan; 30(1):123-33. PubMed ID: 18680205
[TBL] [Abstract][Full Text] [Related]
17. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs.
Vreeswijk MP; Kraan JN; van der Klift HM; Vink GR; Cornelisse CJ; Wijnen JT; Bakker E; van Asperen CJ; Devilee P
Hum Mutat; 2009 Jan; 30(1):107-14. PubMed ID: 18693280
[TBL] [Abstract][Full Text] [Related]
18. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.
Carvalho MA; Marsillac SM; Karchin R; Manoukian S; Grist S; Swaby RF; Urmenyi TP; Rondinelli E; Silva R; Gayol L; Baumbach L; Sutphen R; Pickard-Brzosowicz JL; Nathanson KL; Sali A; Goldgar D; Couch FJ; Radice P; Monteiro AN
Cancer Res; 2007 Feb; 67(4):1494-501. PubMed ID: 17308087
[TBL] [Abstract][Full Text] [Related]
19. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.
Sanz DJ; Acedo A; Infante M; Durán M; Pérez-Cabornero L; Esteban-Cardeñosa E; Lastra E; Pagani F; Miner C; Velasco EA
Clin Cancer Res; 2010 Mar; 16(6):1957-67. PubMed ID: 20215541
[TBL] [Abstract][Full Text] [Related]
20. Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity.
Walker LC; Whiley PJ; Couch FJ; Farrugia DJ; Healey S; Eccles DM; Lin F; Butler SA; Goff SA; Thompson BA; Lakhani SR; Da Silva LM; ; Tavtigian SV; Goldgar DE; Brown MA; Spurdle AB
Hum Mutat; 2010 Jun; 31(6):E1484-505. PubMed ID: 20513136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
